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ABSTRACT 17 
Polyphenols play an important role in human health. To address their accessibility to a breastfed 18 
infant, we planned to evaluate whether breast milk (BM) (colostrum, transitional, and mature) 19 
epicatechin metabolites could be related to the dietary habits of mothers. The polyphenol 20 
consumption of breastfeeding mothers was estimated using a food frequency questionnaire and 24 h 21 
recalls. Solid-phase extraction−ultra performance liquid chromatography−tandem mass spectrometry 22 
(SPE−UPLC−MS/MS) was applied for direct epicatechin metabolite analysis. Their bioavailability 23 
in BM as a result of dietary ingestion was confirmed in a preliminary experiment with a single dose 24 
of dark chocolate. Several host and microbial phase II metabolites of epicatechin were detected in 25 
BM among free-living lactating mothers. Interestingly, a modest correlation between 26 
dihydroxyvalerolactone sulfate and the intake of cocoa products was observed. Although a very low 27 
percentage of dietary polyphenols is excreted in BM, they are definitely in the diet of breastfed 28 
infants. Therefore, evaluation of their role in infant health could be further promoted. 29 
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INTRODUCTION 33 
Human breast milk (BM) is the optimal food for newborns and infants because it supplies nutrients 34 
and biologically active elements that are essential for their development and health.1 Along with its 35 
main nutrients, it also supplies minor compounds, such as vitamins and micronutrients, which play 36 
important roles in the development and health of infants.2 Despite the accumulated knowledge in the 37 
field of dietary polyphenols,3,4 currently, little is known about their bioavailability in human BM of 38 
lactating mothers and their accessibility to breastfed infants. Accordingly, the effect of the 39 
consumption of dietary polyphenols through BM on the health of infants has not yet been widely 40 
studied. Thus far, only a few studies have addressed the question of the excretion of dietary 41 
polyphenols in human BM under controlled dietary ingestion,5−7 and even fewer studies have 42 
addressed their presence in the BM of lactating mothers under free-living conditions.8,9 However, 43 
all of them measured the enzymatically hydrolyzed fraction of corresponding polyphenols, without 44 
taking into account the nature of the metabolites available in BM. Recently, the importance of 45 
investigating the metabolites of dietary polyphenols was highlighted.3 To establish the health effects 46 
of polyphenol intake by infants, it is essential to have information on their disposition in BM, which 47 
is related to the previous dietary intake of a lactating woman. With the intention of assessing the 48 
delivery of polyphenols of a dietary origin to infants through breastfeeding, we planned to estimate 49 
whether the presence of epicatechin metabolites in BM could be related to the dietary habits of 50 
lactating mothers. Cocoa products are among the richest sources of polyphenols in our diets.10 One 51 
of the most well-accepted and widely consumed cocoa products in the world is chocolate. In relation 52 
to the objectives of the present study, we consider dark chocolate (DCh) to be an appropriate food 53 
element to provide close to real-life ingestion of one of the most representative dietary polyphenols: 54 
flavan-3-ols. In addition, the bioavailability of flavanols, especially epicatechin, is one of the most 55 
well-understood among dietary polyphenols11 and has also been extensively studied by our 56 
group.12,13 Therefore, flavanol-rich DCh could be a good dietary choice to approximate the 57 
bioavailability and excretion of epicatechin in BM. In addition, a cocoa component in foods is easy 58 
to track in the dietary records of free-living subjects as a result of its relatively integral consumption 59 
and because its presence in food can be easily recognized and recalled by subjects. Therefore, we 60 
anticipate that the presence in BM of epicatechin metabolites might reflect dietary epicatechin 61 
consumption of either a total or specifically epicatechin-rich food (e.g., cocoa) origin by lactating 62 
women. 63 
 MATERIALS AND METHODS 64 
Study Design, Subjects, and Sampling. Preliminary Experiment on Epicatechin BM 65 
Bioavailability. Two healthy lactating mothers (aged 32 and 37 and weighing 68 and 63 kg, 66 
respectively) in the 6th month of the postpartum period kindly provided their BM (mature milk) at 67 
several time points over a 12 h period on a voluntary basis. Neither woman smoked or took 68 
medication. The acute ingestion of DCh was carried out in the morning, prior to any other food intake. 69 
The DCh consumed was from a domestic supply, and both volunteers reported on the amount (g) 70 
consumed and percentage of cocoa in the chocolate (according to the manufacturer) (Table S1 of the 71 
Supporting Information). During the intervention day, no other cocoa-containing products were 72 
consumed by either volunteer. The women reported their 24 h dietary habits on the day prior to the 73 
collection of BM samples. While total milk was collected from one breast using an electric pump 74 
over defined time periods after acute DCh ingestion, babies were nourished from the other breast on 75 
demand. The volume of collected BM was recorded. Free-Living Population Study. A total of 11 76 
breastfeeding women (mean age of 33.2 years) under free-living conditions participated in the 77 
population study. They were recruited in their 30th week of pregnancy from the Barcelona Science 78 
Park and the San Cecilio University Hospital in Granada (Figure 1). Detailed information on the 79 
eligibility criteria is disclosed in the Supporting Information. All participants had read the study 80 
protocol, approved by the Ethics Committee of San Cecilio University Hospital in Granada and the 81 
Bioethics Committee of the University of Barcelona (IRB00003099), and had signed an informed 82 
consent form. The samples, metrics, and dietary data collection were performed in both recruiting 83 
centers. Manipulation of the samples, evaluation of dietary records, and analyses were performed by 84 
the Barcelona University group. A food frequency questionnaire (FFQ) was provided on the day of 85 
inclusion in the study (Figure 1). After a baby was born, three types of BM samples, colostrum (1−4 86 
days postpartum), transitional (5−15 days postpartum), and mature (>30 days postpartum), and 24 h 87 
dietary recalls (24 h DR) completed on the previous day were collected from each volunteer. Up to 88 
30−50 mL of BM was collected per sample in the morning or through the day using a manual or 89 
electric pump. However, in the course of the study, several dietary records and some BM samples 90 
were not available (Figure 1). All of the collected BM samples (from the preliminary experiment and 91 
population study) were labeled, immediately stored at −20 °C (in home freezers), and shortly 92 
afterward transferred in dry ice to the laboratory freezers, where they were stored at −80 °C until 93 
analysis.  94 
Dietary Assessment of Polyphenol Intake. Food intake (g/ day) was evaluated using three 24 h DR. 95 
Dietary total and individual flavan-3-ol monomer (from here on flavan-3-ols will refer to monomers 96 
only) intake was estimated using our food composition database on polyphenols.14 This was based 97 
on three United States Department of Agriculture (USDA) databases15−17 and the Phenol- Explorer 98 
database.18 The FFQ, developed and validated in the Spanish population,19 was applied on the day 99 
of enrolment to evaluate food intake (g/day) over the previous 3 months by pregnant women in a free-100 
living population study. 101 
Determination of Epicatechins and Their Metabolites in BM Samples. On the day of analysis, a 102 
1 mL aliquot of the BM sample was thawed in an ice bath, acidified with 25 μL of phosphoric acid 103 
(35%), sonicated for 15 min at room temperature, and afterward centrifuged at 15900g for 10 min at 104 
4 °C. Through gentle aspiration, 0.8 mL of acidified aqueous phase of BM was collected and used 105 
for solid-phase extraction (SPE). The concentrations of (−)-epicatechin (EpiCat), O-methyl-106 
epicatechin (MetEpiCat), and colon microbiotagenerated metabolites, such as 5-(3′,4′-107 
dihydroxyphenyl)-γ-valerolactone (DHPV) and 5-(3′-methoxy-4′-hydroxyphenyl)-γ-108 
valerolactone (MHPV), along with their corresponding phase II conjugate sulfates (Sulf) and 109 
glucuronides (Gluc) in BM, were analyzed according to the earlier published methodology,20 with a 110 
slightly modified elution step. Then, the retained epicatechin metabolites were eluted by applying 0.5 111 
mL of basic methanol (0.1% ammonia) after 1 mL of acidified methanol (0.1% formic acid) to 112 
optimize both glucuronide and sulfate extraction (>75% recovery; data not shown).21 The 113 
reconstituted-inmobile- phase samples were used for ultra performance liquid chromatography−114 
tandem mass spectrometry (UPLC−MS/MS) analysis. Ethyl gallate served as the internal standard 115 
(IS). The previously established methodology was used for UPLC−MS/MS analysis of epicatechin 116 
metabolites.12,20 The epicatechin metabolites were identified according to the available standards 117 
(EpiCat, Cat, MetEpiCat, EpiCat-Gluc-2, and EpiCat-Sulf-1) and as a result of the previously 118 
described mass chromatographic behavior of compounds12,20 (Table S2 of the Supporting 119 
Information). Calibration curves were constructed in the range of 5−2000 μg/L with available 120 
standards in aqueous extracts of BM and subjected to the same procedure as the samples. As a result 121 
of the fact that standards for phase II metabolites were not available, the concentrations of all sulfated, 122 
glucuronidated, and methylated metabolites were approximated using curves of in-house synthesized 123 
EpiCat-Sulf-1, EpiCat-Gluc-2, and MetEpiCat, respectively, and the results were expressed as their 124 
equivalents.20 These compounds were synthesized and characterized as previously published.22 The 125 
purity of purchased standards [(−)-epicatechin, (+)-catechin, and ethyl gallate from Sigma-Aldrich 126 
(St. Louis, MO)] was of analytical grade, and the purity of synthesized standards was ≥98, ≥98, and 127 
≥96%, respectively, as reported in our previous studies applying this methodology.12,20 128 
Statistical Analysis. Dietary intake of polyphenols is shown as the mean and standard deviation 129 
(SD). The contribution of each food to total dietary polyphenols and flavan-3-ol intake, in total and 130 
specifically that of cocoa origin, and the contribution of flavan-3-ol to the polyphenol intake were 131 
calculated as a percentage. The Friedman test was used to compare the consumption of polyphenols 132 
among the three phases of lactation. We used Spearman correlations to assess whether flavan-3-ol 133 
and epicatechin intakes were correlated to DHPVSulf- 2. SPSS statistical analysis system, version 134 
18.0 (SPSS), was used, and the significance level for the performed statistical analyses was <0.05. 135 
RESULTS AND DISCUSSION 136 
Epicatechin Metabolites in BM after Acute DCh Ingestion. In accordance with the habitual dietary 137 
consumption evaluated by 24 h DR collected on pre-intervention day, DCh was the principal dietary 138 
source of flavan-3-ols (78− 92%) and epicatechin (92−96%) consumed during the intervention day 139 
by both volunteers (Table S1 of the Supporting Information). In both lactating women, the acute DCh 140 
intervention was estimated to provide an intake of around 80 mg of DCh-derived flavan-3-ol 141 
monomers, of which about 48% corresponded to epicatechin (Table S1 of the Supporting 142 
Information). Therefore, the DCh epicatechin content was estimated to be within the ranges reported 143 
for other commercially available DChs.23  144 
The DCh intake challenge led to the direct identification of two groups of epicatechin metabolites in 145 
the BM samples of both volunteers collected over 12 h after ingestion: (i) host metabolites of 146 
epicatechin, EpiCat-Sulf-1 and EpiCat-Sulf-2, EpiCat-Gluc-4, and Met-EpiCat-Sulf-3, and (ii) 147 
microbial metabolites, DHPV-Sulf-2, DHPV-Gluc-1 and DHPV-Gluc-2, MHPV-Sulf-1 and MHPV-148 
Sulf-2, and MHPV-Gluc-1.12,20 The selected chromatograms of the detected epicatechin 149 
metabolites in the BM samples are represented in Figure S1 of the Supporting Information. 150 
 BM is a special biological compartment linked closely to plasma, but on the other hand, similar to 151 
urine, it can accumulate excreted compounds.24 Although we did not have corresponding standards, 152 
it is very likely that the main detected host metabolites correspond to the major metabolites of 153 
cocoaderived epicatechin recently described in postprandial plasma and urine:25,26 EpiCat-3′-O-154 
Gluc (as EpiCat-Gluc-4), EpiCat- 3′-O-Sulf (as EpiCat-Sulf-2), and 3′-Methyl-EpiCat-5-O-Sulf 155 
(as Met-EpiCat-Sulf-3). In general, their levels in the BM samples were quite low, even at maximum 156 
concentration rates (nmol/L) (Figure S1 of the Supporting Information and panels A and B of Figure 157 
2), being close to the plasmatic postprandial levels detected after intake of 2 times higher dose of 158 
DCh.26 This was also in agreement with the BM ranges of other polyphenols previously reported in 159 
dietary intervention volunteers6−8 and in some populations of free-living lactating mothers.5,9 Other, 160 
less abundant metabolites could not be detected as a result of their very low, several times lower than 161 
detected, metabolite26 concentrations. The changes in the BM concentrations of the detected host 162 
metabolites were very similar in both volunteers (Figure 2B). 163 
 Continuously collected samples from volunteer 2 were used to evaluate the BM excretion kinetics 164 
of detected host epicatechin metabolites over 12 post-intervention hours (Figure 2A). The peaks of 165 
maximum concentration for each metabolite were defined by visual inspection of excretion graphs. 166 
Thus, the highest levels of EpiCat-Sulfs and EpiCat- Gluc metabolites were reached in BM 4 h after 167 
DCh intake and after 6 h for Met-EpiCat-Sulf in both sample sets (Figure 2B). Dietary epicatechin 168 
was rapidly absorbed in the small intestine, and its metabolites were quickly eliminated from plasma 169 
within 6−8 h and excreted in urine.26 Our data showed that the main epicatechin host metabolites 170 
were still present in the BM at detectable levels 12 h after DCh ingestion (panels A and B of Figure 171 
2). According to the dietary recalls, no other potent source of flavanols other than DCh was consumed 172 
on the intervention day by either volunteer (Table S1 of the Supporting Information). Therefore, this 173 
accumulation of DChderived host epicatechin metabolites in the BM resembled that previously 174 
reported for urine, where they were mostly excreted between the 5th and 10th postprandial hour and 175 
were still present at lower concentrations after 10 h.26 Unfortunately, we did not collect either blood 176 
or urine samples from the two volunteers within the present study. However, the relation between the 177 
plasmatic, urinary, and BM kinetics of epicatechin metabolites should be further studied, because it 178 
will indicate in detail the bioavailability, excretion, and accumulation of dietary polyphenols in BM. 179 
In addition to host metabolites, the only microbial-derived metabolite of epicatechin, DHPV-Sulf-2, 180 
was detected in the set of BM samples of volunteer 2 (Table S3 of the Supporting Information). In 181 
contrast, other microbial metabolites were also detected in all of the BM samples of volunteer 1: 182 
DHPV-Sulf-1, DHPV-Gluc-2, MHPV-Sulf-1, MHPV-Sulf-2, and MHPV-Gluc- 1, along with the 183 
most pronounced DHPH-Sulf-2 metabolite (Figure S1 and Table S3 of the Supporting Information). 184 
All of them, except DHPV-Sulf-1, were increasing in concentration toward the end of the BM sample 185 
collection period (12 h). Unfortunately, there are no reported data on the urine or plasmatic kinetics 186 
of microbial ring-fusion metabolites of cocoaderived epicatechin to be compared to our BM results. 187 
According to recently reported data on tea epicatechins,27 first-stage microbial metabolites 188 
(valerolactones) appeared in plasmatic circulation with a 2−4 h lag time and at a maximum 189 
concentration in 4−8 h, exceeding those of host epicatechin metabolites by 1 order of magnitude. 190 
They remained in circulation for about 20 h after single-dose consumption of black tea. On the basis 191 
of these pharmacokinetic data, we assume that the BM kinetics of the microbial metabolites could 192 
not be evaluated within the present study as a result of the relatively short time for postprandial 193 
sample collection. The late appearance of the ring-fusion metabolites in BM is due to the fact that 194 
they are generated through microbiota catabolic activities and, as result, are absorbed in the large 195 
intestine.28 We assume that, in contrast to volunteer 2, who did not consume any cocoa products 196 
prior to the intervention, epicatechin microbial metabolites were detected in the preintervention (0 h) 197 
and early (2−8 h) postprandial samples of volunteer 1 most likely as a result of the consumption of 198 
DCh from the previous day within her habitual diet (data not shown). In general, our data on microbial 199 
epicatechin metabolites are also in line with those previously reported, where the main microbial 200 
metabolite in 24 h urine after longterm cocoa powder consumption was DHPV-Sulf-2, along with the 201 
main host metabolites EpiCat-Gluc-4, EpiCat-Sulf-2, and Met-EpiCat-Sulf-2.12 In support of our 202 
findings, in the study with tea polyphenols, it was observed that sulfated conjugates of valerolactones 203 
were almost twice more represented in plasma than glucuronidated forms.27 Thus, the authors 204 
suggested that sulfation was preferred over glucuronidation at the site of valerolactone metabolism.27 205 
The 2 h fractionated samples from volunteer 2 showed approximated 12 h cumulative excretion of 206 
the detected host metabolites in BM. It was not possible to conduct analysis for volunteer 1, because 207 
the collection of samples was interrupted as a result of lactating circumstances. Thus, the combined 208 
12 h excretion of the host metabolites in BM, expressed in catechin equivalents, was estimated to 209 
account for about 0.01% (assuming equal excretion in both breasts) of the chocolateingested 210 
epicatechin (Table S3 of the Supporting Information). Considering just non-colonic metabolites, the 211 
bioavailability value during the first 12 postprandial hours observed in this study would provide a 212 
breastfed child with about 3.8 μg of catechin equivalent. This approximately corresponds to a 213 
cumulative dose of 0.772 μg/kg (for a baby weighing 5 kg) spread over 12 h,29 when the single dose 214 
of the lactating mother was estimated to be about 0.61 mg/kg (for a woman weighing 63 kg) as DCh-215 
derived epicatechin. Thus, the dose for the child appears to be 3 orders of magnitude lower than that 216 
of the mother. Unfortunately, we cannot take into account the metabolites generated by colonic 217 
microbiota for mother and infant dose approximation, although their weight in relation to epicatechin 218 
metabolism and disposition is expected to be essential.27,28 On the other hand, other potential 219 
sources of epicatechin and valerolactone phase II metabolites, such as procyanidins,12 were not 220 
considered in our preliminary experiment. Estimation of the accessibility of dietary polyphenols to 221 
breastfed infants could be especially relevant in the light of recent reports accentuating their potential 222 
to modulate gut microbiota activities.30,31 223 
Epicatechin in BM of Free-Living Lactating Women. 224 
Among the 11 women participating in our population study, FFQs were collected from 9 volunteers. 225 
All three 24 h DRs were available only for 8 volunteers, whereas the second and third 24 h DRs 226 
(corresponding to transition and mature milk collections) were available for 10 volunteers; for one of 227 
them, it was repeated twice for transition, and for another, it was repeated twice for mature milk 228 
collection (Figure 1 and Table S4 of the Supporting Information). From the 33 samples planned to be 229 
collected for epicatechin metabolite analysis, 4 colostrum samples and 1 mature milk sample from 230 
different volunteers and all three BM samples from one volunteer were not available as a result of 231 
lactating circumstances. In total, 10 volunteers participated in the study, providing 24 BM samples 232 
matched to corresponding dietary records (Figure 1 and Table S4 of the Supporting Information). The 233 
total polyphenol consumption in our population was 1104.97 ± 465.97 mg/day according to the FFQs, 234 
which was higher than that assessed by the 24 h DRs, where the average consumption corresponded 235 
to about 751.58 mg/day (Table S5 of the Supporting Information). According to the FFQs and average 236 
24 h DRs, cocoa polyphenols made a moderate contribution to the total dietary polyphenol 237 
consumption in our free-living population, 8 and 9%, respectively (Table S5 of the Supporting 238 
Information), which was in line with recent data (6.7%) on the south European region.32 In general, 239 
daily flavan- 3-ol consumption by free-living breastfeeding mothers was in the range of 1.8−47.5 240 
mg/day (Table S4 of the Supporting Information), on average 18.29 ± 11.83 mg/day, which was 241 
relatively lower than that recently reported for habitual consumption among Spanish adult males (∼24 242 
mg/day)32 and females (∼26 mg/day).33 However, the impact of cocoa products on the provision of 243 
a relatively small percentage of dietary flavan-3-ols (∼4% of total polyphenols according to the FFQ 244 
and average 24 h DRs) was noticeable: 44% (according to the FFQs) and in the range of 13−54% 245 
during the three stages of lactation (according to the 24 h DRs) (Table S5 of the Supporting 246 
Information). According to the FFQs, DCh was the principal source of flavan-3-ols, providing 23% 247 
of the total flavan-3-ol monomer consumption, followed by cocoa (14%), green tea (9%), apples 248 
(8%), cocoa products (7%), black tea (5%), red grapes (4%), and white grapes (2%) (data not shown). 249 
Thus, cocoa provided on average more than 30% of the flavan-3-ols and about 40% of the epicatechin 250 
consumed within their habitual diet by breastfeeding mothers (Table S5 of the Supporting 251 
Information), which was much higher than the 6.7% reported recently for the southern region of 252 
Europe.32 Among the dietary records matched to BM samples, there were 6 participants who 253 
declared no consumption of cocoa products over the 24 h prior to sample collection (Table S4 of the 254 
Supporting Information). Overall, the consumption of both total polyphenols and flavan-3-ols, 255 
assessed by 24 h DR, did not differ significantly (p = 0.88) among the three lactating periods. Both 256 
global dietary and specifically cocoa origin daily intakes of flavan-3-ols and epicatechin correlated 257 
highly (minimum r > 0.75 at p < 0.025) between the FFQs and the average data from the parallel 24 258 
h DRs (data not shown), thereby ensuring the consistency of our dietary evaluations over time. Using 259 
the previously tested DCh intervention experiment methodology, we were able to detect various 260 
epicatechin metabolites in BM samples collected from free-living lactating mothers (Table S4 of the 261 
Supporting Information). The main phase II host metabolites reported in the preliminary study 262 
(EpiCat-Gluc-4, EpiCat-Sulf-2, and Met-EpiCat-Sulf-3) were sporadically identified in some of the 263 
samples of the population study. On the other hand, the most pronounced metabolite, DHPV-Sulf-2, 264 
which belongs to the colonic microbial epicatechin metabolites, was detected in practically all of the 265 
samples (Table S4 of the Supporting Information), whereas other microbial metabolites were only 266 
detected in some of them. On the whole, the levels of detected host metabolites were low, only up to 267 
several tens of nanomoles per liter (Table S4 of the Supporting Information). A recent study with 268 
free-living lactating mothers reported a higher concentration of epicatechin in BM (63.7−828.5 269 
nmol/L).9 On the one hand, our methodology differs from that applied in the American study, in 270 
which total enzymatically hydrolyzed epicatechin was analyzed. In addition, the collection of BM 271 
samples differs in the methodology. On the other hand, the dietary habits during lactation might be 272 
different among countries, providing distinct dietary uptake of flavan-3-ols. Unfortunately, no data 273 
on the dietary habits of American breastfeeding mothers were collected within the study9 to compare 274 
to our population. Samples collected during the population study corresponded to three different 275 
stages of lactation: colostrum, transition, and mature milk (Figure 1). Changes in the concentration 276 
of the detected metabolites over these periods could not be examined because of their sporadic 277 
detection in a limited number of samples. For the same reason, no correlation studies could be 278 
performed between the epicatechin metabolites detected in BM and the dietary data of volunteers, 279 
with the exception of DHPV-Sulf-2. The levels of DHPV-Sulf-2 detected in practically all of the BM 280 
samples were correlated with the dietary epicatechin and flavan-3-ol consumption reported by both 281 
the FFQ (data not shown) and 24 h DR (Table 1), but no relation was observed. After consideration 282 
of the heterogeneity in the types of cocoa product and in the percentage of cocoa flavan-3- ol 283 
consumption (Table S4 of the Supporting Information) for the three periods of lactation and the 284 
physiological specificity of the colostrum secretion is taken into account,1,34 the colostrum samples 285 
(n = 3) were withdrawn from the analysis. As a result, the analysis performed on the transition and 286 
mature sample sets, as independent ones, showed a moderate positive correlation (r = 0.434; p = 287 
0.049) between 24 h consumption of cocoa epicatechin and levels of detected DHPV-Sulf-2 in these 288 
BM samples (Table 1). The fact that the epicatechin host metabolites were detected in BM only 289 
sporadically but colonic metabolites were detected more often was supported by the data on the BM 290 
kinetics of these metabolites observed in our preliminary bioavailability experiment. In our free-291 
living population, dietary data were recorded 24 h prior to BM sampling, and therefore, the chance 292 
of detecting low-abundant host metabolites would be limited to the late, close-to-sampling 293 
epicatechin consumption as a result of their short circulation time. However, as a result of the 294 
specificity of the colonic metabolism, the appearance of microbial metabolites of epicatechin could 295 
be extended to a much longer period at more elevated levels than host metabolites,12,27 thereby 296 
increasing the possibility of being monitored during an uncontrolled study. Therefore, valerolactones 297 
could be more readily detected in BM and, thus, used in relation to 24 h previous epicatechin 298 
consumption. Although our data showed that the concentration of the main microbial epicatechin 299 
metabolite DHPV-Sulf-2 in BM could be correlated with cocoa epicatechin intake within an 300 
uncontrolled habitual diet, we are aware of the small size of our population. Therefore, a larger study 301 
should be carried out to confirm this association. Our study demonstrates that dietary polyphenols, 302 
such as cocoa-derived epicatechin, are bioavailable to breastfed infants through maternal milk as a 303 
phase II host and colonic microbialderived metabolites. According to the approximated cumulative 304 
excretion data, only a very small amount of dietary-ingested epicatechin could be provided with BM 305 
within the first 12 postprandial hours as host epicatechin metabolites. However, it seems that 306 
microbial metabolites represent another important part of the BM-excreted epicatechin metabolites. 307 
Both host and first-stage microbial metabolites (valerolactones) could even be detected in BM 308 
samples collected from lactating mothers under non-controlled free-living conditions. However, as a 309 
result of its relatively elevated concentration and timely prolonged excretion rates compared to other 310 
epicatechin metabolites, only the principal first-stage microbial metabolite DHPV-Sulf-2 could be 311 
used in correlation analysis. Thus, its presence in BM was modestly correlated with dietary intake of 312 
cocoa epicatechin by breastfeeding mothers during transition and mature periods of lactation. Our 313 
findings provide support for further potential research evaluating the impact of dietary polyphenols 314 
on the health of infants.  315 
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